leadf
logo-loader
viewRecce Pharmaceuticals Ltd

Recce Pharmaceuticals to talk new class of synthetic antibiotics at Proactive’s CEO Sessions

Five companies will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.

Recce Pharmaceuticals Ltd - Recce Pharmaceuticals to talk new class of synthetic antibiotics at Proactive’s CEO Sessions
Recce executive director James Graham will talk about the company’s progress and plans

Recce Pharmaceuticals Ltd (ASX:RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics designed to address the urgent global health problem of antibiotic-resistant superbugs.

The company’s antibiotics are unique – their potency does not diminish even with repeated use, which is a common failure associated with existing antibiotic use and the resulting emergence of resistant superbugs.

Recce executive director James Graham will talk about the company’s progress and plans at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4 along with four other companies.

Fighting antibiotic-resistant superbugs

Recce’s patented lead candidate RECCE 327, wholly-owned and manufactured in Australia, has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms.

The FDA has awarded RECCE 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post-approval.

Efficacy against MRSA superbug

RECCE 327 recently showed significant efficacy against the MRSA superbug in the treatment of burns wound infection in an animal model.

The study was undertaken in co-operation with an established Australian teaching hospital, by an independent contract research organisation.

Top line results showed significant in vivo antibacterial activity against Methicillin-Resistant Staphylococcus aureus (MRSA – superbug) in rats with topical burns: RECCE 327 reduced bacterial load and enhanced wound closure.

A separate human skin model showed the antibiotic was non-irritating, even at high concentrations.

Broad range of clinical treatments

Recce chairman Dr John Prendergast said at the time of publishing the study results: “These data demonstrate that RECCE antibiotics has great potential to be applied in a broad range of clinical treatment settings.

“With significant data synergies from our lead indication in the treatment of sepsis, to another area of urgent unmet need, these new results support Recce’s potential to address the increasing threat of antibiotic-resistant superbugs.”

Five companies presenting

Other companies presenting at the Sydney and Melbourne events are Antisense Therapeutics Limited (ASX:ANP), Great Boulder Resources Ltd (ASX:GBR) and Cynata Therapeutics Ltd (ASX:CYP) while Rewards Minerals Ltd (ASX:RWD) will present in Sydney and Alice Queen Ltd (ASX:AQX) will present in Melbourne.

Register now for the CEO Sessions:

Sydney event, Monday, February 3

Melbourne event, Tuesday, February 4

Quick facts: Recce Pharmaceuticals Ltd

Price: 1.025 AUD

ASX:RCE
Market: ASX
Market Cap: $177.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Recce Pharmaceuticals Ltd named herein, including the promotion by the Company of Recce Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Namaste releases third quarter financial numbers showing year over year...

Namaste Technologies (CVE: N-OTCMKTS: NXTTF) CEO Meni Morim joined Steve Darling from Proactive to share with viewers the company results from Q-3 2020- Morim noting an improvement in Revenue year over year and a better bottom line. Morim also told Proactive about the real bright spot for the...

18 minutes ago

3 min read